-
公开(公告)号：US20110207122A1
公开(公告)日：2011-08-25
申请号：US12596462
申请日：2008-04-17
申请人： Shigeru Kinoshita , Kei Tashiro , Masakazu Nakano , Tomohito Yagi , Kazuhiko Mori , Yoko Ikeda , Takazumi Taniguchi , Masaaki Kageyama
发明人： Shigeru Kinoshita , Kei Tashiro , Masakazu Nakano , Tomohito Yagi , Kazuhiko Mori , Yoko Ikeda , Takazumi Taniguchi , Masaaki Kageyama
CPC分类号： C12Q1/6886 , C12Q1/6883 , C12Q2600/156
摘要： A method of determining the presence or the absence of a glaucoma risk, including the steps of detecting in vitro an allele and/or a genotype of a single nucleotide polymorphism which is located on a 31st base of a base sequence, in a sample from a subject, wherein the base sequence is at least one base sequence selected from the group consisting of base sequences shown in SEQ ID NOs: 203 to 752 or a complementary sequence thereto (step A), and comparing the allele and/or the genotype detected in the step A with at least one of an allele and/or a genotype, containing a high-risk allele, in the base sequences shown in SEQ ID NOs: 203 to 752 (step B). According to the method of the present invention, the level of a progressive risk of glaucoma in a sample donor can be determined by analyzing an allele or a genotype of a single nucleotide polymorphism in the present invention in the sample, so that the sample donor can take a preventive measure of glaucoma, or can receive appropriate treatments, on the basis of this risk.
摘要翻译： 一种确定青光眼风险的存在或不存在的方法，包括以下步骤：在位于碱基序列的第31位的单核苷酸多态性的体外检测等位基因和/或基因型， 其中所述碱基序列是选自SEQ ID NO：203至752所示的碱基序列或其互补序列的至少一种碱基序列（步骤A），并比较检测到的等位基因和/或基因型 在SEQ ID NO：203〜752（步骤B）所示的碱基序列中具有含有高风险等位基因的等位基因和/或基因型中的至少一种的步骤A。 根据本发明的方法，可以通过分析样品中本发明的单核苷酸多态性的等位基因或基因型来确定样品供体中青光眼进行性风险的水平，使得样品供体可以 采取预防措施的青光眼，或者可以根据这种风险接受适当的治疗。
-
2.发明授权Nucleic acid participating in the formation of presenilin-2-gene exon 5-defective splicing variant 失效核酸参与早老素-2基因外显子5缺陷剪接变体的形成公开(公告)号：US07364847B2
公开(公告)日：2008-04-29
申请号：US10482115
申请日：2002-06-27
CPC分类号： C07K14/4711 , C12Q1/6883 , C12Q2600/156 , G01N33/6896 , G01N2500/00
摘要： The present invention provides a means for treatment and/or prevention of a disease caused by aberrant splicing, a neurodegenerative disease represented by Alzheimer's disease, or the like. The present invention relates to a nucleic acid which can be associated with generation of a splice variant that lacks exon 5 of presenilin-2 gene, an inhibitor for inhibiting a binding between protein-nucleic acid caused by aberrant splicing, and a method for screening the inhibitor.
摘要翻译： 本发明提供了治疗和/或预防由异常剪接引起的疾病，由阿尔茨海默病代表的神经变性疾病等的方法。 本发明涉及可以与缺少早老素-2基因的外显子5的剪接变体的产生相关联的核酸，抑制由异常剪接引起的蛋白质 - 核酸之间的结合的抑制剂，以及用于筛选 抑制剂。
-
3.发明授权Dibekacin derivatives and arbekacin derivatives active against resistant bacteria, and the production thereof 失效对抗性细菌有活性的二比卡星衍生物和阿贝卡星衍生物及其生产
公开(公告)号：US5618795A
公开(公告)日：1997-04-08
申请号：US524644
申请日：1995-09-08
申请人： Shinichi Kondo , Seiji Shibahara , Takayuki Usui , Toshiaki Kudo , Shuichi Gomi , Atsushi Tamura , Yoko Ikeda , Daishiro Ikeda , Tomio Takeuchi
发明人： Shinichi Kondo , Seiji Shibahara , Takayuki Usui , Toshiaki Kudo , Shuichi Gomi , Atsushi Tamura , Yoko Ikeda , Daishiro Ikeda , Tomio Takeuchi
IPC分类号： C07H15/236 , A61K31/70
CPC分类号： C07H15/234
摘要： As new dibekacin derivatives and new arbekacin derivatives are now provided 2"-amino-2"-deoxydibekacin, 2"-amino-5,2"-dideoxydibekacin, 2"-amino-2"-deoxyarbekacin, 2"-amino-5,2"-dideoxyarbekacin, 2"-amino-5,2"-dideoxy-5-epi-fluoroarbekacin and 2"-amino-5,2"-dideoxy-5-epi-aminoarbekacin which all exhibit high antibacterial activity against a wide variety of gram-positive and gram-negative bacteria, including resistant bacteria such as methicillin-resistant Staphylococcus aureus and which are of low toxicity to mammals and are useful as antibacterial agent for treatment of bacterial infections.
摘要翻译： 现在提供新的二卡辛衍生物和新的阿贝卡星衍生物2' - 氨基-2' - 脱氧胆碱，2“ - 氨基-5,2” - 脱氧胆酸，2“ - 氨基-2'-脱氧阿糖胞苷，2 “ - 氨基-5,2” - 双脱氧肉豆蔻素，2“ - 氨基-5,2” - 双脱氧-5-表 - 氟代贝卡星和2“ - 氨基-5,2” - 双脱氧-5-表 所有这些都表现出对各种革兰氏阳性和革兰氏阴性细菌的高抗菌活性，包括耐甲氧西林金黄色葡萄球菌等抗性细菌，对哺乳动物毒性低，可用作细菌治疗的抗菌剂 感染。
-
公开(公告)号：US20130210668A1
公开(公告)日：2013-08-15
申请号：US13850453
申请日：2013-03-26
申请人： Shigeru KINOSHITA , Kei Tashiro , Masakazu Nakano , Tomohito Yagi , Kazuhiko Mori , Yoko Ikeda , Takazumi Taniguchi , Masaaki Kageyama
发明人： Shigeru KINOSHITA , Kei Tashiro , Masakazu Nakano , Tomohito Yagi , Kazuhiko Mori , Yoko Ikeda , Takazumi Taniguchi , Masaaki Kageyama
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q1/6883 , C12Q2600/156
摘要： A method of determining the presence or the absence of a glaucoma risk, including the steps of detecting in vitro an allele and/or a genotype of a single nucleotide polymorphism which is located on a 31st base of a base sequence, in a sample from a subject, wherein the base sequence is at least one base sequence selected from the group consisting of base sequences shown in SEQ ID NOs: 203 to 752 or a complementary sequence thereto (step A), and comparing the allele and/or the genotype detected in the step A with at least one of an allele and/or a genotype, containing a high-risk allele, in the base sequences shown in SEQ ID NOs: 203 to 752 (step B). According to the method of the present invention, the level of a progressive risk of glaucoma in a sample donor can be determined by analyzing an allele or a genotype of a single nucleotide polymorphism in the present invention in the sample, so that the sample donor can take a preventive measure of glaucoma, or can receive appropriate treatments, on the basis of this risk.
摘要翻译： 一种确定青光眼风险的存在或不存在的方法，包括以下步骤：在位于碱基序列的第31位的单核苷酸多态性的体外检测等位基因和/或基因型， 其中所述碱基序列是选自SEQ ID NO：203至752所示的碱基序列或其互补序列的至少一种碱基序列（步骤A），并比较检测到的等位基因和/或基因型 在SEQ ID NO：203〜752（步骤B）所示的碱基序列中具有含有高风险等位基因的等位基因和/或基因型中的至少一种的步骤A。 根据本发明的方法，可以通过分析样品中本发明的单核苷酸多态性的等位基因或基因型来确定样品供体中青光眼进行性风险的水平，使得样品供体可以 采取预防措施的青光眼，或者可以根据这种风险接受适当的治疗。
-
公开(公告)号：US07759072B2
公开(公告)日：2010-07-20
申请号：US11817515
申请日：2006-03-02
申请人： Koji Ushizawa , Michiko Kawamoto , Shoko Yamamoto , Kumiko Yuki , Yoko Ikeda , Mitsuaki Yamamoto
发明人： Koji Ushizawa , Michiko Kawamoto , Shoko Yamamoto , Kumiko Yuki , Yoko Ikeda , Mitsuaki Yamamoto
IPC分类号： G01N33/53
CPC分类号： G01N33/581 , G01N33/5306 , G01N33/542 , G01N33/54393
摘要： The present invention provides a novel immunoassay method with high reaction specificity and high sensitivity. The present invention also provides a method for immunoassaying a target antigen utilizing reactivation of an apoenzyme, which includes simultaneously or sequentially adding a test sample to an antibody specific to the target antigen, the target antigen labeled with a coenzyme, an apo-D-amino acid oxidase, a D-amino acid, and a reagent for detecting a hydrogen peroxide produced by the oxidase.
摘要翻译： 本发明提供了具有高反应特异性和高灵敏度的新型免疫测定方法。 本发明还提供了使用辅酶的再活化来免疫测定靶抗原的方法，其包括同时或依次将测试样品加入到靶抗原特异性抗体中，用辅酶标记的靶抗原，载脂蛋白-D-氨基 酸性氧化酶，D-氨基酸和用于检测由氧化酶产生的过氧化氢的试剂。
-
公开(公告)号：US20050065102A1
公开(公告)日：2005-03-24
申请号：US10482103
申请日：2002-06-27
IPC分类号： C12N15/09 , A61K31/7105 , A61K31/711 , A61K38/00 , A61K45/00 , A61K48/00 , A61P9/10 , A61P25/00 , A61P25/16 , A61P25/28 , A61P43/00 , C07K14/47 , C07H21/02
CPC分类号： C07K14/4702 , A61K38/00 , A61K48/00 , C07K14/4711
摘要： To provide a means useful for treating or preventing a disease such as a brain disorder or a neurodegenerative disease even more efficiently and even more sustainedly. The present invention relates to an inhibitor capable of inhibiting a binding between HMG-I protein and exon 5 of presenilin-2 mRNA, an agent for suppressing neuronal death, capable of suppressing neuronal death, a pharmaceutical composition which is useful for treatment or prevention of a disease caused by the generation of a splice variant that lacks exon 5 of presenilin-2 mRNA, a method for treating or preventing the disease and a use of the inhibitor.
摘要翻译： 提供用于更有效地甚至更持久地治疗或预防诸如脑部疾病或神经变性疾病的疾病的方法。 本发明涉及能够抑制HMG-1蛋白与早老蛋白-2 mRNA的外显子5之间的结合的抑制剂，抑制神经元死亡的能力，能够抑制神经元死亡的药剂组合物，其可用于治疗或预防 由缺乏早老素-2 mRNA的外显子5的剪接变体的产生引起的疾病，治疗或预防疾病的方法和抑制剂的使用。
-
公开(公告)号：US20060274932A1
公开(公告)日：2006-12-07
申请号：US11431709
申请日：2006-05-11
申请人： Yoko Ikeda , Junko Konishi , Hisafumi Iwata , Yuji Takagi , Kenji Obara , Ryo Nakagaki , Seiji Isogai , Yasuhiko Ozawa
发明人： Yoko Ikeda , Junko Konishi , Hisafumi Iwata , Yuji Takagi , Kenji Obara , Ryo Nakagaki , Seiji Isogai , Yasuhiko Ozawa
CPC分类号： G06F3/0486 , G06F2203/04803 , G06T7/0004 , G06T2200/24 , G06T2207/30148
摘要： A method for classifying defects, including: calculating feature quantifies of defect image which is obtained by imaging a defect on a sample; classifying the defect image into a classified category by using information on the calculated feature quantities; displaying the classified defect image in a region on a display screen which is defined to the classified category; adding information on the classified category to the displayed defect image; transferring the displayed defect image which is added the information on the classified category to one of the other categories and displaying the transferred defect image in a region on the display screen which is defined to the one of the other categories; and changing information on the category.
-
8.发明授权Dibekacin derivatives and arbekacin derivatives active against resistant bacteria 失效敌百虫素衍生物和对抗性细菌有活性的阿贝卡星衍生物
公开(公告)号：US5488038A
公开(公告)日：1996-01-30
申请号：US154002
申请日：1993-11-18
申请人： Shinichi Kondo , Seiji Shibahara , Takayuki Usui , Toshiaki Kudo , Shuichi Gomi , Atsushi Tamura , Yoko Ikeda , Daishiro Ikeda , Tomio Takeuchi
发明人： Shinichi Kondo , Seiji Shibahara , Takayuki Usui , Toshiaki Kudo , Shuichi Gomi , Atsushi Tamura , Yoko Ikeda , Daishiro Ikeda , Tomio Takeuchi
IPC分类号： C07H15/236 , A61K31/70 , C07H15/22
CPC分类号： C07H15/234
摘要： As new dibekacin derivatives and new arbekacin derivatives are now provided 2"-amino-2"-deoxydibekacin, 2"-amino-5,2"-dideoxydibekacin, 2"-amino-2"-deoxyarbekacin, 2"-amino-5,2"-dideoxyarbekacin, 2"-amino-5,2"-dideoxy-5-epi-fluoroarbekacin and 2"-amino-5,2"-dideoxy-5-epi-aminoarbekacin which all exhibit high antibacterial activity against a wide variety of gram-positive and gram-negative bacteria, including resistant bacteria such as methicillin-resistant Staphylococcus aureus and which are of low toxicity to mammals and are useful as antibacterial agent for treatment of bacterial infections.
摘要翻译： 现在提供新的二卡辛衍生物和新的阿贝卡星衍生物2' - 氨基-2' - 脱氧胆碱，2“ - 氨基-5,2” - 脱氧胆酸，2“ - 氨基-2'-脱氧阿糖胞苷，2 “ - 氨基-5,2” - 双脱氧肉豆蔻素，2“ - 氨基-5,2” - 双脱氧-5-表 - 氟代贝卡星和2“ - 氨基-5,2” - 双脱氧-5-表 所有这些都表现出对各种革兰氏阳性和革兰氏阴性细菌的高抗菌活性，包括耐甲氧西林金黄色葡萄球菌等抗性细菌，对哺乳动物毒性低，可用作细菌治疗的抗菌剂 感染。
-
9.发明申请Comprehensive Glaucoma Determination Method Utilizing Glaucoma Diagnosis Chip And Deformed Proteomics Cluster Analysis 审中-公开综合青光眼测定方法利用青光眼诊断芯片和变形蛋白质组学分析公开(公告)号：US20130275349A1
公开(公告)日：2013-10-17
申请号：US13976967
申请日：2011-12-28
申请人： Kei Tashiro , Shigeru Kinoshita , Tomohito Yagi , Masakazu Nakano , Kazuhiko Mori , Yoko Ikeda , Morio Ueno , Yuichi Tokuda , Katsumi Yagi , Kengo Yoshii , Masahiro Fuwa
发明人： Kei Tashiro , Shigeru Kinoshita , Tomohito Yagi , Masakazu Nakano , Kazuhiko Mori , Yoko Ikeda , Morio Ueno , Yuichi Tokuda , Katsumi Yagi , Kengo Yoshii , Masahiro Fuwa
IPC分类号： G06N99/00
CPC分类号： G06N20/00 , C12Q1/6886 , G16B20/00 , G16B25/00 , G16B40/00
摘要： Provided is a technique for determining a physiological attribute in a mammal, including the onset or progression of human glaucoma, with high accuracy. The results of the determination of genotype date and the results of the determination of cytokine date are consolidated by a consolidated determination unit (114); comparison is made for determining as to which is larger, the number of Case determination procedures or the number of control determination procedures (S330); and it is determined as Case (glaucoma) when the number of Case determination procedures is larger and it is determined as Control (normal person) when the number of Control determination procedures is larger.
摘要翻译： 提供了一种用于以高精度确定哺乳动物的生理属性，包括人类青光眼的发病或进展的技术。 确定基因型日期的结果和细胞因子日期的确定结果由综合确定单位（114）合并; 比较确定哪个更大，判定程序的数量或控制确定程序的数量（S330）; 当判定判定过程的数量较多并且当控制确定过程的数量较大时被确定为控制（普通人）时被确定为病例（青光眼）。
-
公开(公告)号：US08431345B2
公开(公告)日：2013-04-30
申请号：US12596462
申请日：2008-04-17
申请人： Shigeru Kinoshita , Kei Tashiro , Masakazu Nakano , Tomohito Yagi , Kazuhiko Mori , Yoko Ikeda , Takazumi Taniguchi , Masaaki Kageyama
发明人： Shigeru Kinoshita , Kei Tashiro , Masakazu Nakano , Tomohito Yagi , Kazuhiko Mori , Yoko Ikeda , Takazumi Taniguchi , Masaaki Kageyama
CPC分类号： C12Q1/6886 , C12Q1/6883 , C12Q2600/156
摘要： A method of determining the presence or the absence of a glaucoma risk, including the steps of detecting in vitro an allele and/or a genotype of a single nucleotide polymorphism which is located on a 31st base of a base sequence, in a sample from a subject, wherein the base sequence is at least one base sequence selected from the group consisting of base sequences shown in SEQ ID NOs: 203 to 752 or a complementary sequence thereto (step A), and comparing the allele and/or the genotype detected in the step A with at least one of an allele and/or a genotype, containing a high-risk allele, in the base sequences shown in SEQ ID NOs: 203 to 752 (step B). According to the method of the present invention, the level of a progressive risk of glaucoma in a sample donor can be determined by analyzing an allele or a genotype of a single nucleotide polymorphism in the present invention in the sample, so that the sample donor can take a preventive measure of glaucoma, or can receive appropriate treatments, on the basis of this risk.
摘要翻译： 一种确定青光眼风险的存在或不存在的方法，包括以下步骤：在位于碱基序列的第31位的单核苷酸多态性的体外检测等位基因和/或基因型， 其中所述碱基序列是选自SEQ ID NO：203至752所示的碱基序列或其互补序列的至少一种碱基序列（步骤A），并比较检测到的等位基因和/或基因型 在SEQ ID NO：203〜752（步骤B）所示的碱基序列中具有含有高风险等位基因的等位基因和/或基因型中的至少一种的步骤A。 根据本发明的方法，可以通过分析样品中本发明的单核苷酸多态性的等位基因或基因型来确定样品供体中青光眼进行性风险的水平，使得样品供体可以 采取预防措施的青光眼，或者可以根据这种风险接受适当的治疗。
-
-
-
-
-
-
-
-
-
搜索结果
21 条记录 (耗时 0.025 秒)
